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PSevere Myocardial Fibrosis Caused by a
Deletion of the 5’ End of the Lamin A/C Gene
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Stefan J. White, PHD, Johan T. den Dunnen, PHD, Gerard J. te Meerman, PHD,*
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Groningen, Maastricht, and Leiden, the Netherlands
Objectives The goal of this study was to identify the underlying gene defect in a family with inherited myocardial fibrosis.
Background A large family with an autosomal dominantly inherited form of myocardial fibrosis with a highly malignant clini-
cal outcome has been investigated. Because myocardial fibrosis preceded the clinical and echocardiographic
signs, we consider the disease to be a hereditary form of cardiac fibrosis.
Methods Twenty-five family members were clinically evaluated, and 5 unaffected and 8 affected family members were
included in a genome-wide linkage study.
Results The highest logarithm of the odds (LOD) score (LOD  2.6) was found in the region of the lamin AC (LMNA)
gene. The LMNA mutation analysis, both by denaturing gradient gel electrophoresis and sequencing, failed to
show a mutation. Subsequent Southern blotting, complementary deoxyribonucleic acid sequencing, and multi-
plex ligation-dependent probe amplification analysis, however, revealed a deletion of the start codon-containing
exon and an adjacent noncoding exon. In vitro studies demonstrated that the deletion results in the formation of
nuclear aggregates of lamin, suggesting that the mutant allele is being transcribed.
Conclusions This novel LMNA deletion causes a distinct, highly malignant cardiomyopathy with early-onset primary cardiac
fibrosis likely due to an effect of the shortened mutant protein, which secondarily leads to arrhythmias and
end-stage cardiac failure. (J Am Coll Cardiol 2007;49:2430–9) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.063c
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iilated cardiomyopathy (DCM) is characterized by dilata-
ion and impaired contractile function of the left ventricle.
he mortality rate is high, with the 5-year survival rate
round 50% (1). The incidence is about 4 of 10,000/year,
aking it one of the most important reasons for cardiac
ransplantation (2). Up to 50% of cases lack an underlying
iagnosis, which justifies its classification as “idiopathic”
ilated cardiomyopathy (IDCM) (3).
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edical Center Groningen, University of Groningen, Groningen, the Netherlands;
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ccepted February 12, 2007.The familial character of IDCM has become increasingly
lear in that several recent studies have shown that up to
5% of all IDCM patients have at least 1 affected (first-
egree) relative (4–7). In at least 60% of these familial
DCM cases, an autosomal-dominant inheritance pattern is
uggested (6–8).
Among the most frequently reported genetic causes of
CM, identified in up to 30% of cases of DCM in
ssociation with cardiac conduction disease or supraventric-
lar arrhythmias, are mutations in the gene encoding lamin
and C (LMNA) proteins (9,10).
Dilated cardiomyopathy is clinically highly variable, en-
ompassing the spectrum from frank dilatation with rela-
ively little fibrosis to less dilative forms with more severe
erangement of myocardial histology. Myocardial fibrosis
ccompanies virtually all forms of cardiomyopathy, includ-
ng inherited forms, and is therefore commonly regarded to
e a secondary phenomenon. The idea that fibrosis is
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June 26, 2007:2430–9 Inherited Cardiac Fibrosis Due to an LMNA Deletionecondary to heart failure has been fueled by the fact that
enetic defects that give rise to extensive primary myocardial
brosis have not as yet been described.
In presenting here a large family with a hereditary form of
arly onset cardiac fibrosis, we will be addressing the
uestion of whether primary myocardial fibrosis can be
onsidered as a separate disease entity or should be regarded
s a subphenotype of DCM.
ethods
nvestigated family and cardiological investigations. The
nvestigated family has been known at our hospital for
early 50 years (11). As part of our clinical genetic-
ounseling procedure, we asked patients to inform relatives
bout the possibility of genetic counseling and cardiological
valuation. Patients who were investigated gave their writ-
en informed consent. To establish the clinical phenotype,
lectrocardiographic recording, exercise testing, echocardi-
graphy, signal-averaged electrocardiography, and 24-h
lectrocardiography were performed. Owing to the exten-
ive and early fibrosis that has been described this family
11), all family members suspected of being affected (as
ndicated by atrioventricular blockade or supraventricular
rrhythmias on 24-h Holter monitoring) underwent a
ight-ventricular endomyocardial biopsy (EMB) after ob-
aining a fully normal coronary angiogram that included a
eft ventricular angiogram.
istology. Paraffin sections of EMB and postmortem
ull-thickness sections of right and left ventricular myocar-
ium were stained with hematoxylin and eosin. A Masson
richrome stain was used to determine the amount of
ollagen. Patients with manifest (interstitial) fibrosis were
onsidered as being affected.
eoxyribonucleic acid isolation. Blood samples were col-
ected from all marked-affected and unaffected subjects of
Figure 1 Pedigree of the Family
Solid symbols indicate clinically and genetically affected persons (deletion carriers
examination or from medical records or literature (11). Open symbols indicate clin
Squares represent men, and circles represent women. *The respective person ha
sudden cardiac death.he family involved (Fig. 1).
enomic deoxyribonucleic acid
DNA) was extracted from pe-
ipheral blood leukocytes with
he salting-out procedure (12).
inkage analysis. Genome-
ide mapping was performed
ith approximately 300 fluorescent
icrosatellite markers (ISOGEN
ioscience, Maarsen, the Nether-
ands), spread over the entire ge-
ome with an average resolution of
0 cM. DeCODE, Marshfield, and
enethon human-linkage maps
ere used as guidance for inter-
arker distances.
Standard polymerase chain-
eaction (PCR) amplification
as performed in 20 l contain-
ng 150 ng of genomic DNA and
0 pmol of fluorescently labeled
rimers. Reaction products from 4 to 8 markers were pooled
nd separated on an automatic ABI 377 DNA sequencer or
n a MegaBACE 1000. Marker analysis was performed
ith the GENESCAN v3.1 and GENOTYPER v2.5
oftware (Applied Biosystems, Foster City, California),
espectively. Linkage analysis was performed with Gronlod
13) with a 5% recombination frequency, a penetrance of
0%, and a phenocopy rate of 10%.
enaturing gradient-gel electrophoresis and sequence
nalysis of the LMNA gene. Point-mutation analysis for
he LMNA gene was performed with both denaturing
radient-gel electrophoresis (DGGE) and sequencing.
hirteen amplicons were analyzed with both methods (J. P.
an Tintelen, unpublished data, 2005; primers available
pon request).
-quarter black-filled symbols indicate those clinically affected upon personal
naffected individuals and line-through symbols indicate deceased individuals.
evaluated genetically. The haplotypes are represented in Table 2. SCD 
Abbreviations
and Acronyms
DCM  dilated
cardiomyopathy
DGGE  denaturing
gradient gel
electrophoresis
DNA  deoxyribonucleic
acid
EMB  endomyocardial
biopsy
IDCM  idiopathic dilated
cardiomyopathy
LMNA  lamin AC
MLPA  multiplex ligation-
dependent probe
amplification
PCR  polymerase chain
reaction
RNA  ribonucleic acid). One
ically u
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Inherited Cardiac Fibrosis Due to an LMNA Deletion June 26, 2007:2430–9For sequencing, PCR products were purified with the
igh Pure PCR Product Purification Kit (Boehringer
annheim, Mannheim, Germany) and then sequenced
ith the Thermo Sequenase Kit (Amersham Life Science,
uckinghamshire, United Kingdom) or the Sequenase kit
USB, Cleveland, Ohio).
outhern blots. Genomic DNA (8 g) was digested either
ith BamHI and XbaI or with Bgl2 and EcoRV. The DNA
ragments were separated overnight by gel electrophoresis in
0.7% agarose gel and were transferred under denaturing
onditions (0.4 mol/l sodium hydroxide and 0.6 mol/l
odium chloride) to a Hybond N membrane. The filters
ere rinsed, air-dried, and baked at 80°C for 2 h. Prehy-
ridization was carried out in a 0.5 mol/l phosphate buffer,
% sodium dodecyl sulfate (SDS), 1.0 mmol/l ethylene-
iaminetetraacetic acid (EDTA) solution for 30 min at
5°C and hybridization in fresh solution overnight with
32P]dCTP-labeled LMNA complementary DNA
cDNA) probe (a 2027 base pair [bp] insert of an LMNA
DNA [IMAGp958B1610Q2]). Filters were washed twice
n 2  standard saline citrate (SSC), 0.1% SDS at 65°C for
5 min, and in 1  SSC, 0.1% SDS for 15 min, and in 0.3
SSC, 0.1% SDS for 10 min at 65°C. After washing the
lot was exposed to X-ray Kodak XAR film with intensi-
ying screens at 80°C for several days.
DNA analysis. Ribonucleic acid (RNA; 2.5 g), isolated
rom deletion carrier III-12, was used to make cDNA with
he Ready-To-Go You-Prime-First-Strand Beads Kit
Amersham Biosciences) according to the manufacturer’s
rotocol. This cDNA was used to perform PCR with the
xon 2 forward primer (CGGAGATCTCAGAG-
CACCGAC) and an exon 3 reverse primer (GCAG-
ATCTCATCCTGAAGT). The PCR products were
urified and sequenced as described previously.
ultiplex ligation-dependent probe amplification. For
he detection of large deletions or duplications of whole
xons, we also used the multiplex ligation-dependent probe
mplification (MLPA) test (MRC-Holland, Amsterdam,
he Netherlands) (14,15). The probe mix contains 8 coding
xon probes for the LMNA gene (exons 1, 2, 3, 4, 6, 7, 8,
nd 10). In addition, we designed a set containing 3
djacent non-coding exon probes (numbered 1, 2 and
3, respectively, where exon 1 is adjacent to the LMNA
ene) at the 5’ region of the LMNA gene and 4 control
robes specific for DNA sequences outside the LMNA
ene.
ell culture, immunoblotting, and indirect immunofluo-
escence. Human dermal fibroblasts from a patient and an
naffected relative were cultured at 37°C under 5% carbon
ioxide in Dulbecco’s Modified Eagle’s Medium, supple-
ented with 10% fetal bovine serum.
Cells were counted and plated in 6-well plates, allowed to
ttach for 24 h, and lysed with the sample buffer. Protein
amples were sheared through a 23G needle and boiled at
5°C for 10 min. Proteins were separated in 8% acrylamid
els and transferred onto polyvinylidene fluoride (PDVF) aembranes. Primary antibodies against lamins A and C
Jol2, gift from Dr. C. J. Hutchison, Durham, United
ingdom) and GAPDH (RDI TRK5G4-6C5) were incu-
ated overnight at 4°C in 3.5% Protifar plus (Nutricia,
oetermeer, the Netherlands) in TRIS-buffered saline,
.1% Tween. The secondary antibody, rabbit anti-mouse
gG HRP-linked, was visualized with enhanced chemolu-
inescence.
For immunofluorescence studies, cells were plated on
overslips, allowed to attach for 24 h, and fixed in 3.7%
ormaldehyde. Cells were permeabilized with 0.1% Triton and
tained with primary antibody against lamin A (133a2) and
ounterstained with FITC-conjugated rabbit anti-mouse IgG
F0232, DAKO, Heverlee, Belgium). Immunofluorescence-
abeled cells were counterstained with the DNA dye 4’-6-
iamidino-2-phenylindole (DAPI). Nuclear aggregates of 100
eparate nuclei were counted.
esults
linical and histopathological evaluation. We evaluated
9 individuals from 3 generations (Fig. 1); generation II has
een described previously (11). Twenty-five family members
isited us for screening starting in 1995 (11 men, 14
omen). We studied the clinical records and postmortem
xaminations of 4 additional persons (3 women) who had
ied (III-3, -7, -8, and -11) (Fig. 1). No signs of neuro-
uscular disease or lipodystrophy were noted. Creatine
hosphokinase (CPK) values were within normal limits.
wo patients (III-17 and -18) died during follow-up.
Of the 29 family members we studied, 18 were suspected
o be affected either on clinical grounds or because of
remature death (Fig. 1). Of these 18 subjects, 15 were
istologically investigated: 13 underwent EMB (4 of these
ith additional postmortem or post-transplantation exam-
nations). In 2 patients only postmortem investigations were
vailable. Myocardial fibrosis was found in 14 of these 15
istologically investigated subjects. In 4 of these (III-12,
II-15, IV-8, IV-9) (Table 1), distinct pathological fibrosis
as identified as compared with the more extensive fibrosis
n the remaining 10 patients. In patient IV-6, EMB showed
brolipomatosis that could not be distinguished from ar-
hythmogenic right ventricular cardiomyopathy. Histologi-
al postmortem examinations of full-thickness myocardium
n 5 patients (III-3, -7, -11, -17, and -18) all demonstrated
xtensive areas of interstitial and replacement fibrosis
hroughout the left and right ventricular myocardium and
xtensive fibrosis of the cardiac conduction system. The
efinite diagnosis was decided on the basis of a positive
iopsy or postmortem histological proof of fibrosis.
More importantly, fibrosis (III-15, IV-2, -5, -8, and -9)
r fibrolipomatosis (IV-6) was detected in 6 subjects who
id not exhibit any abnormalities on echocardiography; in 4
f them (III-15, IV-2, IV-5, and IV-6) palpitations were
he only complaint. In asymptomatic subjects, a first-degree
trioventricular block or supraventricular tachycardias raised
Clinical Characteristics of Mutation Carriers and Individual IV-6
Table 1 Clinical Characteristics of Mutation Carriers and Individual IV-6
No. in
Pedigree Gender
Age
Diagnosis
Referred for
CCD
(age)
AF
(age)
VPB
(h)/
VTs NSVT
Age
at
Echo
LV Dilation Age
at
Death
(yrs)
Cause of
Death
Myocardial
PA
Biopsy
(B) (age)/
Autopsy
(A) (age)Palpitations Dyspnea
CVA/
Thrombosis Screening
LV
Function LVEDD LVESD
III-3 F 34  1st-degree
AVB (34)
 (34) 58; 2  44 NL 38 27 60 Pneumonia
due to
ALS
extensive
fibrosisCS
B (54)/A (60)
III-7 F 50  AVB (50)  (50) NA NA 53 Progr HF extensive
fibrosisCS
A (53)
III-8 F 22  LBBB (22)  (35) NA 40 PR 45 39 46 Progr HF fibrosis B (40)
III-11 M 49 NA NA NA NA 49 SCD extensive
fibrosisCS
A (49)
III-12 F 42  LBBB (42)  (42) 284; 1  42 PR 55 45   fibrosis B (48)
III-14 M 40  1st-degree
AVB (40)
 (48) 15; 0  36 NL 54 37  No abnor-
malities
B (47)
III-15 F 20  1st-degree
AVB (27)
 318; 0  43 NL 46 27   fibrosis B (43)
III-17 M 43  aspec IV
CD
 (44) 90; 3  45 PR 50 38 49 Progr HF fibrosisCS B (45)/A (49)
III-18 M 40   LBBB (40)  (40) 474; 4  40 PR 52 45 41 SCD fibrosisCS B (40)/A (41)
III-19 F 45  1st-degree
AVB (47)
 (47) 70; 0  47 NL 46 25 NA
IV-2 F 42   1st-degree
AVB (42)
 (42) 3; 0  42 NL 50 29  fibrosis B (42)
IV-5 F     1; 0  39 NL 51 24 fibrosis B (39)
IV-6 F 35     1; 0  36 NL 46 30 fibro-
lipomatosis
B (36)
IV-7 M 30  1st-degree
AVB
 4; 0  32 NL 51 40   NA
IV-8 M 33    63; 0  33 NL 55 35   distinct
fibrosis
B (33)
IV-9 F 26    2; 0  26 NL 41 28   distinct
fibrosis
B (26)
IV-11 M 26  1st-degree
AVB (26)
 9; 0  26 NL 48 32   NA 
IV-14 M 20  LBBB 1,547; 4  20 PR 69 61 HTX  diffuse
fibrosis
B (20)/post Htx
AF  atrial fibrillation; ALS  amyotrophic lateral sclerosis; aspec  aspecific; AVB  atrioventricular block; CCD  cardiac conduction disease; CS  conduction system; HF  heart failure; Htx  heart transplantation; IV CD  intraventricular conduction delay; LBBB 
left bundle branch block; LV  left ventricular; LVEDD  left ventricular end diastolic diameter; LVESD  left ventricular end systolic diameter; NA  not available; NL  normal; NSVT  non-sustained ventricular tachycardias; PA  pathological anatomy; PR  poor; Prog
 progressive; SCD  sudden cardiac death; VPB  ventricular premature beat.
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Inherited Cardiac Fibrosis Due to an LMNA Deletion June 26, 2007:2430–9he suspicion that they might be affected, which resulted in
he treating physician ordering an EMB, which revealed
brosis.
Thus, of all 14 of the affected family members with
athological interstitial myocardial fibrosis, 5 had cardiac
brosis and 1 had fibrolipomatosis without any important
oss of left ventricular function. The clinical data and
urvival curve for these patients are shown in Table 1 and
igure 2.
enetic analysis. Genome-wide linkage screening yielded
he highest logarithm of the odds (LOD) score (LOD score
2.6) for the region containing the LMNA gene. The
aplotypes around this gene and individuals studied are
hown in Table 2. Besides this region, no other regions
howed a LOD score over 1.5. Although linkage was not
ompletely conclusive, the gene was screened for point
utations with DGGE and direct-sequence analysis. These
nalyses did not reveal any sequence variation. Subsequent
I-18 III-19 III-2 III-5 III-6
391 403
232 228* 232 232 228 232 232 232 232
178 186* 178 186 178† 186 178 186 178
193 183* 193 183 193† 193 193 193 193
201 201* 201 191 197† 201 197 201 197
208 218* 208 220 208† 220 216 220 216
202 202* 202 210 214†
202 202* 206 202 204† 202 202 202 202
186 190* 186 186 190† 186 186 186 186
285 277* 289 277 277† 277 285 277 285
del*
165 169* 161 161 159† 161 165 161 165
148 152* 150 150 150† 150 150 150 150
153 161 163 163 145† 145 145 145 145
176 178 176 174 192† 174 188 174 188
221 221 211 217 217† 217 219 219 221
V-9 IV-10 IV-11 III-12 IV-14
387 387
228 228 228 236 236 224 224
186 178 186 184 186 178 186 178 182
193 183 183 193 191 193 193 193 195
195 191 191 201 191 201 205 201 197
214 194 216 212 194 212 214 212 220
210 210 208 210 214
204 204 202 202* 204 202* 204 202* 204
190 186 186 190* 186 190* 186 190* 186
277 285 285 277* 285 277* 285 277* 289
del* del* del*
169 169 165 169* 169 169* 169 169* 159
150 148 150 152* 148 152* 152 152* 148
161 161 145 157 163 157 149 157 165
196 170 188 178 192 178 176 178 176
215 215 219 221 213 221 219 221 213
non-affected” maternal allele also identified in the unaffected maternal aunt III-2. †”Non-affected”Figure 2 Kaplan-Meier Survival Curve
Kaplan-Meier curve with end points cardiac death or cardiac transplantation.aplotypes Around the LMNA Gene
Table 2 Haplotypes Around the LMNA Gene
Dst cM Marker II-11 Wife of II-13 III-17 II
1669 373* 373*
99.6 1665 228 228 232 232 228*
105.3 0430 178 178 186*
110 2766 185 193 185 193 183* 193 183*
126.7 0248 201 201 197 201 201* 201 201*
135.4 2881 208 218 208 208 218* 208 218*
140.7 0534 202 204 202* 202 202*
147.3 D1S0305 202 208 202 206 202* 206 202*
148.6 D1S0303 186 186 186 186 190* 186 190*
148.9 D1S1595 285 289 285 289 277* 289 277*
149 LMNA del* del*
150.4 D1S2624 159 169 165 161 169* 161 169*
154.3 D1S2635 144 146 148 150 152* 150 152*
1679 153 157 153 163 145 163 161
165.8 2878 174 174 176 176 186 176 178
169.7 0431 217 221 221 211 215 211 221
Dst cM Marker
Husband of
III-7 IV-6 IV-8 I
1669 391 403
99.6 1665 228 228 228
105.3 0430 178 178‡ 178‡ 178† 178
110 2766 185 193‡ 193‡ 193† 193 193 193
126.7 0248 197 195‡ 195‡ 197† 201* 195 201*
135.4 2881 212 214‡ 214‡ 208† 218* 214 218*
140.7 0534 202* 210 202*
147.3 D1S0305 206 204‡ 204‡ 204† 202* 204 202*
148.6 D1S0303 186 190‡ 190‡ 190† 190* 190 190*
148.9 D1S1595 289 277‡ 277‡ 277† 277* 277 277*
149 LMNA del* del*
150.4 D1S2624 169 169‡ 169‡ 159† 169* 169 169*
154.3 D1S2635 148 150‡ 150‡ 150† 152* 150 152*
1679 149 153‡ 153‡ 145† 157 157 161
165.8 2878 196 196‡ 196‡ 192† 178 196 178
169.7 0431 215 215‡ 215‡ 217† 221 215 221
Haplotypes associated with the lamin AC (LMNA) deletion (del); this demonstrates that IV-6 received the “
the husband of III-7.
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June 26, 2007:2430–9 Inherited Cardiac Fibrosis Due to an LMNA Deletionouthern blot analysis with 2 different double digests showed a
eletion of the exon containing the start codon of the
MNA gene (Fig. 3). The PCR on cDNA revealed 2 PCR
roducts of approximately 900 and 250 bp in length (Fig.
). Subsequent sequence analysis showed that the longest
DNA fragment contained all exons, whereas the shorter
and was lacking exons 1 and 1 of the LMNA gene
Fig. 5). This resulted in a deletion of 674 bp, which
xplains the 2 different-sized bands on the agarose gel.
ubsequent MLPA analysis confirmed the deletion of exon
(Table 3), whereas the other coding exons had been
etained. Because of technical difficulties in the design of the
rimers, a deletion of exon 1 could not be confirmed with
his technique.
Deoxyribonucleic acid samples were available for 16 of
he 18 clinically affected family members. The LMNA dele-
ion was identified in all but 1 (IV-6) of these 16 persons.
creening IDCM patients for LMNA deletion. Investi-
ations in 150 additional patients with familial and non-
amilial DCM (with or without cardiac conduction disease
Figure 3 Southern Blot Analysis of LMNA
Deletion Carriers and Control Subjects
Southern blot showing reduced intensities of the signal corresponding with the
start codon–containing exon of the lamin AC (LMNA) gene in affected patients
(IV-8, IV-9, IV-11) as compared with control subjects (C) and a nonaffected fam-
ily member (IV-10).nd/or supraventricular arrhythmias) and in a control groupf 150 unaffected persons have not revealed any further
ntragenic LMNA deletions.
ell culture studies. To assess the effect of this novel
eletion on the expression of lamins, we performed Western
lot and indirect immunofluorescence assays. Western blot
nalysis of lamins A and C clearly showed decreased
xpression of both normal-sized lamins A and C in cells
rom a mutation carrier, when compared with the expression
f the control cells (Fig. 6). Indirect immunofluorescence
learly showed an increased number of nuclear aggregates in
ells from a lamin mutation carrier but hardly any aggregates
n control cells (Fig. 7) (0.54 [SEM 0.10] in control cells vs.
.05 [SEM 0.32] in cells from an LMNA mutation carrier
p  0.0001]).
iscussion
n a family with early onset myocardial fibrosis, we identi-
ed a deletion of the 5’ end of the LMNA gene including
he start codon containing exon, located in the region of the
ighest LOD score. The LOD score at this locus did not
xceed 2.6, because individual IV-6, referred for palpitations
nd initially classified as clinically affected, neither showed
Figure 4 PCR on Complementary Deoxyribonucleic Acid
Reverse transcription polymerase chain reaction (RT-PCR) on ribonucleic acid
(RNA) extracted from fibroblasts of patient III-12 and from lymphocytes of a
control individual. The RNA of the patient show, in addition to the normal-sized
band, a shorter product that after sequencing proved to have lost both exons
1 and 1. The normal-sized product is weaker, owing to the fact that shorter
amplicons are more abundantly amplified.
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Inherited Cardiac Fibrosis Due to an LMNA Deletion June 26, 2007:2430–9inkage to this region nor had the deletion. Her EMB
howed fibrolipomatosis that could not be distinguished
rom arrhythmogenic right ventricular cardiomyopathy. We
herefore consider the clinical picture of IV-6 a phenocopy
nrelated to the inherited disorder in other family members.
Southern blot analysis indicated a deletion that was
ubsequently confirmed by PCR on cDNA and MLPA.
estern blot analysis did show decreased expression of both
amins A and C in fibroblasts from a mutation carrier as
ompared with a non-carrier, although no alternative prod-
ct from the mutated allele was seen (Fig. 6). An explana-
ion for this might be that the truncated protein is less
table.
It is striking that fibrosis was massive and so easily
ncountered at biopsy. In 6 patients cardiac fibrosis was
resent before cardiac function was clearly affected as judged
y echocardiography. Although it cannot be excluded that
brosis is secondary to loss of a small number of myocytes as
eactive fibrosis, this severe fibrosis occurs early in the
isease and seems less likely to be secondary to overt failure.
evere myocardial fibrosis was also noted in the majority of
Figure 5 Sequence Analysis of cDNA in Deletion Carrier and Co
Forward complementary deoxyribonucleic acid (cDNA) sequence and schematic rep
of the 5’ region of the lamin AC gene on cDNA level in the wild type (A) and mutahe first families described by Fatkin et al. (9) as having tCM due to LMNA gene mutations, and also fibrosis of
keletal muscles has been noted before (16,17). The early
ccurrence of severe cardiac fibrosis in the absence of
ardiac-function loss in the presented family practically
xcludes that cardiac fibrosis is caused by overt, severe heart
ailure but is initiated very early in the course of the disease.
ur finding of nuclear aggregates of lamin in cultured
broblasts from a mutation carrier substantiates the effect of
his deletion. This raises the possibility that other LMNA
ene mutations might also cause primary fibrosis, thus
orming the underlying pathology in this cardiac phenotype.
athophysiologic effect of the LMNA deletion contain-
ng the start codon. The LMNA gene encodes lamins A
nd C by means of alternative splicing. These proteins are
ajor components of the nuclear lamina, a fibrous network
nderlying the inner surface of the nuclear envelope (18).
utations in the lamin A/C gene have been reported in a
ariety of disorders, such as autosomal dominant and
ecessive Emery-Dreifuss muscular dystrophy (19,20); limb-
irdle muscular dystrophy type 1B (21); autosomal recessive
harcot-Marie-Tooth disease type 2B1 (22); Dunnigan-
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27,28); atypical Werner’s syndrome (29); and lipoatrophy
ith diabetes, hepatic steatosis, hypertrophic cardiomyopa-
hy, and leukomelanodermic papules (30). Finally, LMNA
ene mutations have been identified in patients having
DCM with conduction disease (11) or “pure” DCM
31,32). The exact pathophysiological mechanism of
MNA mutations that lead to such an impressive hetero-
eneous spectrum of disorders has not yet been elucidated.
owever, myocardial fibrosis as a secondary phenomenon
as been described before in different laminopathies
10,15,33).
The identified deletion of the 5’ end of the LMNA gene
ontaining the start codon is predicted to affect mainly the
ead domain of lamin (that is, it might lead to a shortened
rotein lacking the head domain). Assuming that the
eletion does not interfere with the splicing of the other
xons, new potential translation initiation sites should lie at
DNA position 559 and 598 (amino acids 187 and 200,
espectively). When these proteins are produced, they lack
he N-terminal region of lamin A and C, resulting in a
maller protein, which lacks the head domain. Previously,
argeted mutation studies in Chinese hamster ovary cells
ave shown that functional disruption of the head domain
as dominant negative effects, because these aberrant pro-
eins can form aggregates of lamin in the nucleus (34). In
ine with this in vitro observation, we also found an
Figure 6 Western Blot Analysis of
Lamins A and C in Fibroblasts
Western blot analysis showing decreased expression of both lamins A and C in
fibroblasts from mutation carrier (B), as compared with a non-carrier family
member (A). No alternative product from the mutated allele was seen. Glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) serves as a control that equal
amounts of protein have been loaded.increased number of lamin nuclear aggregates in culturedT E E E E E E E Av
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irtual absence of these aggregates in a non-deletion carrier
amily member. This suggests that the mechanisms identi-
ed in vitro (34) do cause cardiac pathology in vivo possibly
ia a dominant negative effect. This raises the possibility
hat other LMNA gene mutations might also cause primary
brosis, thus forming the underlying pathology of this
ardiac phenotype.
o lamin A/C mutations cause a specific cardiac pheno-
ype? The large pedigree made it possible to clinically
valuate patients at the earliest sign of being affected (that is,
hen demonstrating subtle cardiac (supraventricular) ar-
hythmias or cardiac conduction disease). The LMNA
utations can give rise to cardiac conduction disease (10).
he histopathological substrate for the occurrence of con-
uction disease, however, remains unclear. We were, how-
ver, able to demonstrate that pathological myocardial
brosis occurs at the first signs of conduction delay in a
elatively large number of the family members affected. At
ostmortem examinations, extensive fibrosis of the conduc-
ion system was especially notable, because in 6 of the
atients cardiac fibrosis was present before cardiac function
as clearly affected as judged by echocardiography.
Another distinct finding was the small extent of dilatation
or a mutant gene often described as a cause of DCM.
espite severe cardiac complications in laminopathies, this
bservation has been made before (35–39). Therefore these
ombined data suggest that LMNA mutations might cause
distinct cardiomyopathy, characterized by fibrosis and
Figure 7 Indirect Immunofluorescence
Assay With Lamin A Antibody
Indirect immunofluorescence with lamin A antibody showing nuclear lamin
aggregates in fibroblasts from mutation carrier but not in control fibroblasts.
DAPI  4’-6-diamidino-2-phenylindole.ather limited cardiac dilatation, which suggests a distinctisease entity within the spectrum of idiopathic “dilated”
ardiomyopathy. This implies that distinct forms of cardio-
yopathy can be encountered and that LMNA mutations
ight give rise to a type of cardiomyopathy in which
rimary fibrosis drives the specific pathophysiology on a
ighly malignant course. Myocardial fibrosis, therefore,
ight not occur as a separate disease entity but rather as a
ubphenotype of DCM.
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